US 12,280,172 B2
Multi-putty bone hemostatic and adhesive compositions for use in methods of installing and securing surgical hardware in bones
John Pacifico, Greenwich, CT (US); Aniq Darr, Riverdale, NY (US); and Richard L. Kronenthal, Fair Lawn, NJ (US)
Assigned to Abyrx, Inc., Stamford, CT (US)
Filed by Abyrx, Inc., Stamford, CT (US)
Filed on Jan. 31, 2022, as Appl. No. 17/588,653.
Claims priority of provisional application 63/298,439, filed on Jan. 11, 2022.
Claims priority of provisional application 63/143,172, filed on Jan. 29, 2021.
Prior Publication US 2022/0241457 A1, Aug. 4, 2022
Int. Cl. A61L 24/00 (2006.01); A61B 17/86 (2006.01); A61L 24/02 (2006.01); A61B 17/00 (2006.01)
CPC A61L 24/001 (2013.01) [A61B 17/8615 (2013.01); A61B 17/8625 (2013.01); A61B 17/864 (2013.01); A61L 24/0042 (2013.01); A61L 24/02 (2013.01); A61B 2017/00951 (2013.01); A61L 2400/04 (2013.01); A61L 2400/06 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A composition formed by mixing a first component and a second component together,
wherein the first component comprises 30% to 40% of a polyfunctional isocyanate compound, less than 0.5% of one or more polyols, and 50% to 65% of a particulate component, based upon the total weight of the first component,
wherein the particulate material of the first component comprises 1% to 10% of barium sulfate, 1% to 2% of calcium stearate and 48% to 53% of calcium phosphate, based upon the total weight of the first component,
wherein the second component comprises 3% to 5% of a polyfunctional isocyanate compound, 0.5 to 15% of one or more polyols, and 70% to 85% of a particulate component, based upon the total weight of the second component,
wherein the particulate material of the second component comprises 0.1% to 0.5% of calcium stearate and 70% to 75% of calcium phosphate,
wherein the one or more polyols comprise polycaprolactone triol, butanediol, and triethanolamine,
wherein the composition comprises 0.5% to 8.5% of barium sulfate, 0.2% to 1% of calcium stearate and 50% to 65% of calcium phosphate based on the total weight of the composition, and
wherein the concentration of butanediol is 0% to 0.25% of the total weight of the composition.